Listed

CareCloud, Inc.: Form 10-Q for the period ended Mar 31, 2019

Filed with the SEC on May 8, 2019 and accepted by EDGAR at May 8, 2019, 16:31 ET.

Share

Management's discussion and analysis

As filed, 39,372 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following is a discussion of our consolidated financial condition and results of operations for the three months ended March 31, 2019 and 2018, and other factors that are expected to affect our prospective financial condition. The following discussion and analysis should be read together with our Condensed Consolidated Financial Statements and related notes beginning on page 4 of this Quarterly Report on Form 10-Q.

Some of the statements set forth in this section are forward-looking statements relating to our future results of operations. Our actual results may vary from the results anticipated by these statements. Please see “Forward-Looking Statements” on page 2 of this Quarterly Report on Form 10-Q.

Overview

MTBC, Inc., (formerly Medical Transcription Billing, Corp.), together with its consolidated subsidiaries (the “Company”), is a healthcare information technology company that provides a suite of proprietary web-based solutions and business services to healthcare providers. Our integrated Software-as-a-Service (“SaaS”) platform and business services are designed to help our clients increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. These solutions and services include:

Healthcare IT:

  • Revenue cycle management (“RCM”) services;
  • Proprietary, healthcare IT solutions, which are part of our RCM services, including:
  • Electronic health records,
  • Practice management software and related tools,
  • Mobile Health (“mHealth”) solutions,
  • Healthcare claims clearinghouse, and
  • Business intelligence, customized applications, interfaces and a variety of other technology solutions that support our healthcare clients.
  • Group purchasing services.

Practice Management:

  • Comprehensive practice management services.

We are able to deliver our industry-leading solutions at very competitive prices because we leverage a combination of our proprietary software, which automates our workflows and increases efficiency, together with our team of experienced health industry experts throughout the United States, who are supported by our highly educated and specialized offshore workforce of approximately 2,000 team members at labor costs that we believe are approximately one-tenth the cost of comparable U.S. employees. Our unique business model has also allowed us to become a leading consolidator in our industry sector, in which we have gained a reputation for being able to acquire and transform distressed competitors into profitable operations of MTBC.

During July 2018, the Company acquired substantially all of the revenue cycle management, practice management and group purchasing assets of Orion Healthcorp, Inc. and 13 of its affiliates (together, “Orion”). The Company paid $12.6 million in cash for the acquisition. This acquisition expanded the scope of our offerings to include additional niche hospital solutions, a service that negotiates vaccine discounts with pharmaceutical manufacturers and then extends those vaccine discounts to physician members, and a service that provides end-to-end practice management services to physician practices under multi-decade management service agreements.

Adoption of our RCM solutions requires little or no upfront expenditure by a practice. Additionally, for most of our solutions and customers, our financial performance is linked directly to the financial performance of our clients because the vast majority of our revenues are based on a percentage of our clients’ collections. The standard fee for our complete, integrated, end-to-end solution is among the lowest in the industry. We currently provide services to more than 11,000 providers, (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services) practicing in approximately 1,800 independent medical practices and hospitals.

Our offshore operations in Pakistan and Sri Lanka accounted for approximately 18% and 32% of total expenses for the three months ended March 31, 2019 and 2018, respectively. A significant portion of those foreign expenses were personnel-related costs (approximately 80% and 79% for the three months ended March 31, 2019 and 2018). Because personnel-related costs are significantly lower in Pakistan and Sri Lanka than in the U.S. and many other offshore locations, we believe our offshore operations give us a competitive advantage over many industry participants. We are able to achieve significant cost reductions as leverage technology to reduce manual work and strategically transition a portion of the remaining manual tasks to our highly-specialized, cost-efficient team in the U.S., Pakistan and Sri Lanka.

Key Performance Measures

We consider numerous factors in assessing our performance. Key performance measures used by management, including adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share, are non-GAAP financial measures, which we believe better enable management and investors to analyze and compare the underlying business results from period to period.

These non-GAAP financial measures should not be considered in isolation, or as a substitute for or superior to, financial measures calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Moreover, these non-GAAP financial measures have limitations in that they do not reflect all the items associated with the operations of our business as determined in accordance with GAAP. We compensate for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis, and we provide reconciliations from the most directly comparable GAAP financial measures to the non-GAAP financial measures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

Adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share provide an alternative view of performance used by management and we believe that an investor’s understanding of our performance is enhanced by disclosing these adjusted performance measures.

Adjusted EBITDA excludes the following elements which are included in GAAP net income (loss):

  • Income tax (benefit) expense or the cash requirements to pay our taxes;
  • Interest expense, or the cash requirements necessary to service interest on principal payments, on our debt;
  • Foreign currency gains and losses and other non-operating expenditures;
  • Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
  • Depreciation and amortization charges;
  • Integration costs, such as severance amounts paid to employees from acquired businesses, transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees, exit costs related to contractual agreements and restructuring charges arising from discontinued facilities and operations; and
  • Changes in contingent consideration.

23

Set forth below is a presentation of our adjusted EBITDA for the three months ended March 31, 2019 and 2018:

($ in thousands)

Three Months Ended March 31, 2019 2018
Net revenue $15,080 $8,307
GAAP net (loss) income $(296) $75
(Benefit) provision for income taxes (41) 47
Net interest expense 17 69
Foreign exchange / other expense 244 (147)
Stock-based compensation expense 758 128
Depreciation and amortization 757 591
Integration, transaction and restructuring costs 205 179
Change in contingent consideration (64) 32
Adjusted EBITDA $1,580 $974

Adjusted operating income and adjusted operating margin exclude the following elements which are included in GAAP operating income (loss):

  • Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
  • Amortization of purchased intangible assets;
  • Integration costs, such as severance amounts paid to employees from acquired businesses, transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees, exit costs related to contractual agreements, and restructuring charges arising from discontinued facilities and operations; and
  • Changes in contingent consideration.

24

Set forth below is a presentation of our adjusted operating income and adjusted operating margin, which represents adjusted operating income as a percentage of net revenue, for the three months ended March 31, 2019 and 2018:

($ in thousands)

Three Months Ended March 31, 2019 2018
Net revenue $15,080 $8,307
GAAP net (loss) income $(296) $75
(Benefit) provision for income taxes (41) 47
Net interest expense 17 69
Other expense (income) - net 82 (152)
GAAP operating (loss) income (238) 39
GAAP operating margin (1.6)% 0.5%
Stock-based compensation expense 758 128
Amortization of purchased intangible assets 486 361
Integration, transaction and restructuring costs 205 179
Change in contingent consideration (64) 32
Non-GAAP adjusted operating income $1,147 $739
Non-GAAP adjusted operating margin 7.6% 8.9%

Adjusted net income and adjusted net income per share exclude the following elements which are included in GAAP net income (loss):

  • Foreign currency gains and losses and other non-operating expenditures;
  • Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
  • Amortization of purchased intangible assets;
  • Integration costs, such as severance amounts paid to employees from acquired businesses, transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees, exit costs related to contractual agreements, and restructuring charges arising from discontinued facilities and operations;
  • Changes in contingent consideration; and
  • Income tax (benefit) expense resulting from the amortization of goodwill related to our acquisitions.

25

No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes. The following table shows our reconciliation of GAAP net (loss) income to non-GAAP adjusted net income for the three months ended March 31, 2019 and 2018:

($ in thousands)

Three Months Ended March 31, 2019 2018
GAAP net (loss) income $(296) $75
Foreign exchange / other expense 244 (147)
Stock-based compensation expense 758 128
Amortization of purchased intangible assets 486 361
Integration, transaction and restructuring costs 205 179
Change in contingent consideration (64) 32
Income tax (benefit) expense related to goodwill (56) 38
Non-GAAP adjusted net income $1,277 $666

Set forth below is a reconciliation of our non-GAAP adjusted net income per share to our GAAP net loss attributable to common shareholders, per share:

Three Months Ended March 31, 2019 2018
GAAP net loss attributable to common shareholders, per share $(0.15) $(0.06)
Impact of preferred stock dividend 0.13 0.07
Net (loss) income per end-of-period share (0.02) 0.01
Foreign exchange / other expense 0.02 (0.01)
Stock-based compensation expense 0.06 0.01
Amortization of purchased intangible assets 0.04 0.03
Integration, transaction and restructuring costs 0.02 0.02
Change in contingent consideration (0.01) 0.00
Income tax (benefit) expense related to goodwill (0.00) 0.00
Non-GAAP adjusted net income per share $0.11 $0.06
End-of-period shares 12,009,742 11,665,174

For purposes of determining non-GAAP adjusted net income per share, the Company used the number of common shares outstanding at the end of March 31, 2019 and 2018. Non-GAAP adjusted net income per share does not take into account dividends paid on our preferred stock. No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per common share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes.

Key Metrics

In addition to the line items in our consolidated financial statements, we regularly review the following metrics. We believe information on these metrics is useful for investors to understand the underlying trends in our business.

Providers and Practices Served: As of March 31, 2019, we provided services to an estimated universe of more than 11,000 providers (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services), representing approximately 1,800 independent medical practices and hospitals. In addition, we served approximately 200 clients who were not medical practices, but are service organizations who serve the healthcare community. As of March 31, 2018, we served approximately 3,400 providers representing approximately 750 practices. The foregoing numbers include clients leveraging any of our products or services and are based in part upon estimates in cases where the precise number of practices or providers is unknown.

Sources of Revenue

Revenue: We primarily derive our revenues from revenue cycle management services, reported in our Healthcare IT segment, which is typically billed as a percentage of payments collected by our customers. This fee includes RCM, as well as the ability to use our EHR and practice management software as part of the bundled fee. All of these services are considered revenue cycle management revenue. These payments accounted for approximately 70% and 88% of our revenues during the three months ended March 31, 2019 and 2018, respectively. Other Healthcare IT services, including printing and mailing operations and professional services, represented approximately 9% and 12% of revenues for the three months ended March 31, 2019 and 2018, respectively.

As a result of the Orion acquisition, we earned approximately 20% of our revenue from practice management services during the three months ended March 31, 2019. This revenue represents fees based on our actual costs plus a percentage of the operating profit and is reported in our Practice Management segment. Also commencing July 1, 2018, we earned approximately 1% of our revenue during the three months ended March 31, 2019 from group purchasing services which are reported in our Healthcare IT segment.

Operating Expenses

Direct Operating Costs. Direct operating cost consists primarily of salaries and benefits related to personnel who provide services to our customers, claims processing costs, costs to operate the three managed practices, including facility lease costs, supplies, insurance and other direct costs related to our services. Costs associated with the implementation of new customers are expensed as incurred. The reported amounts of direct operating costs do not include depreciation and amortization, which are broken out separately in the condensed consolidated statements of operations.

Selling and Marketing Expense. Selling and marketing expense consists primarily of compensation and benefits, commissions, travel and advertising expenses.

Research and Development Expense. Research and development expense consists primarily of personnel-related costs and third-party contractor costs.

General and Administrative Expense. General and administrative expense consists primarily of personnel-related expense for administrative employees, including compensation, benefits, travel, facility lease costs and insurance, software license fees and outside professional fees.

Contingent Consideration. Contingent consideration represents the portion of consideration payable to the sellers of some of our acquisitions, the amount of which is based on the achievement of defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period.

Depreciation and Amortization Expense. Depreciation expense is charged using the straight-line method over the estimated lives of the assets ranging from three to ten years. Amortization expense is charged on either an accelerated or on a straight-line basis over a period of three or four years for most intangible assets acquired in connection with acquisitions including those intangibles related to the group purchasing services. Amortization expense related to the value of our practice management clients is amortized on a straight-line basis over a period of twelve years.

Interest and Other Income (Expense). Interest expense consists primarily of interest costs related to our working capital line of credit, term loans and amounts due in connection with acquisitions, offset by interest income. Other income (expense) results primarily from foreign currency transaction gains (losses) and income earned from temporary cash investments.

Income Tax. In preparing our condensed consolidated financial statements, we estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred income tax assets and liabilities. Although the Company is forecasting a return to profitability, it incurred cumulative losses, which make realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all deferred tax assets as of March 31, 2019 and December 31, 2018.

Critical Accounting Policies and Estimates

We prepare our condensed consolidated financial statements in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions about future events, and apply judgments that affect the reported amounts of assets, liabilities, revenue, expense and related disclosures. We base our estimates, assumptions and judgments on historical experience, current trends and various other factors that we believe to be reasonable under the circumstances. The accounting estimates used in the preparation of our condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. On a regular basis, we review our accounting policies, estimates, assumptions and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. The methods, estimates and judgments that we use in applying our accounting policies have a significant impact on our results of operations.

Critical accounting policies are those policies used in the preparation of our condensed consolidated financial statements that require management to make difficult, subjective, or complex adjustments, and to make estimates about the effect of matters that are inherently uncertain.

We account for revenue in accordance with ASC 606, Revenue from Contracts with Customers. Our revenue recognition policies require us to make significant judgments and estimates, particularly as it relates to revenue cycle management and group purchasing revenue. Under ASC 606, certain significant accounting estimates, such as payment-to-charge ratios, effective billing rates and the estimated contractual payment periods are required to measure the revenue cycle management revenue. To measure group purchasing services revenue, we need to estimate the number of providers purchasing vaccines and the amount and timing of those purchases. We analyze various factors including, but not limited to, contractual terms and conditions, the credit-worthiness of our customers and our pricing policies. Changes in judgment on any of the above factors could materially impact the timing and amount of revenue recognized in a given period.

Revenue cycle management services:

Most of our revenue cycle management contracts contain variable consideration and we estimate the variable consideration which we expect to be entitled to over the contractual period associated with our revenue cycle management contracts, which begins no earlier than go-live and recognize the fees over the term. When a contract includes variable consideration, we evaluate the estimate of the variable consideration to determine whether the estimate needs to be constrained; therefore, we include the variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For the majority of our revenue cycle management contracts, the total contractual price is variable because our obligation is to process an unknown quantity of transactions, as and when requested by our customers, over the contract period. We allocate the variable price to each claim processed using the time-series concept and recognize revenue based on the most likely amount of consideration to which we will be entitled to, which is generally the amount we will have the right to invoice. Estimates to determine the variable consideration such as payment to charge ratios, effective billing rates, and the estimated contractual payment periods are updated at each reporting date.

Practice management services:

We estimate the variable consideration which we expect to be entitled to for the group purchasing services based upon anticipated shipments to the medical providers enrolled in the program, seasonality and the changes in the number of providers. The estimate of variable consideration includes adjusting historical data for anticipated changes from prior periods. When reviewing our estimates, in order to ensure that our estimates do not pose a risk of significantly overstating our revenue in any reporting period, we will apply constraints, when appropriate, to certain estimates around our variable consideration. Variable consideration estimates are updated at each reporting period.

Although we believe that our approach to estimates and judgements is reasonable, actual results could differ, and we may be exposed to increases or decreases in revenue that could be material. Our estimates of variable consideration may prove to be inaccurate, in which case we may have understated or overstated the revenue recognized in an accounting period. The amount of variable consideration recognized to date that remains subject to estimation is included within the contract asset on the condensed consolidated balance sheet.

Revenue is recognized as the performance obligations are satisfied. We derive revenue from seven primary sources: revenue cycle management services, practice management services, professional services, ancillary services, group purchasing services, printing and mailing services, and clearinghouse and EDI (electronic data interchange) services. All of our revenue arrangements are based on contracts with customers. Most of our contracts with customers contain single performance obligations, although certain contracts do contain multiple performance obligations. We account for individual performance obligations separately if they are distinct. For contracts where we provide multiple services such as where we perform multiple ancillary services, each service represents its own performance obligation. Selling or transaction prices are based on the contractual price for the service.

Leases:

We adopted ASU 2016-02: Leases (Topic 842) as of January 1, 2019. We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liability (current portion) and operating lease liability (noncurrent portion) in our condensed consolidated balance sheet at March 31, 2019. The Company does not have any finance leases.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.

We use our estimated incremental borrowing rates, which are derived from information available at the lease commencement date, in determining the present value of lease payments. We give consideration to bank financing arrangements, geographical location and collateralization of assets when calculating our incremental borrowing rates.

Our lease term includes options to extend the lease when it is reasonably certain that we will exercise that option. Leases with a term of less than 12 months are not recorded in the condensed consolidated balance sheet. Our lease agreements do not contain any residual value guarantees. For real estate leases, we account for the leased and non-leased components as a single lease component. Some leases include escalation clauses and termination options that are factored into the determination of the future lease payments when appropriate.

Other than the adoption of ASC 842, there have been no material changes in our critical accounting policies and estimates from those described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 20, 2019.

Results of Operations

The following table sets forth our consolidated results of operations as a percentage of total revenue for the periods shown:

Three Months Ended March 31, 2019 2018
Net revenue 100.0% 100.0%
Operating expenses:
Direct operating costs 65.3% 54.0%
Selling and marketing 2.4% 3.7%
General and administrative 27.6% 31.3%
Research and development 1.7% 3.1%
Change in contingent consideration (0.4)% 0.4%
Depreciation and amortization 5.0% 7.1%
Total operating expenses 101.6% 99.6%
Operating (loss) income (1.6)% 0.4%
Interest expense - net 0.1% 0.8%
Other (expense) income - net (0.5)% 1.8%
(Loss) income before income taxes (2.2)% 1.4%
Income tax (benefit) provision (0.3)% 0.6%
Net (loss) income (1.9)% 0.8%

Comparison of the three months ended March 31, 2019 and 2018

Three Months Ended March 31, 2019 2018 Change Amount Percent
Net revenue $15,080,211 $8,307,325 $6,772,886 82%

Revenue. Total revenue of $15.1 million for the three months ended March 31, 2019 increased by $6.8 million or 82% from revenue of $8.3 million the three months ended March 31, 2018, respectively. Revenue for the three months ended March 31, 2019 includes approximately $7.7 million from customers acquired in the Orion acquisition. Of this amount, $4.5 million relates to RCM clients and other revenue streams, $3.0 million relates to practice management services and $200,000 relates to group purchasing services.

Three Months Ended March 31, 2019 2018 Change Amount Percent
Direct operating costs $9,847,540 $4,484,055 $5,363,485 120%
Selling and marketing 361,399 305,014 56,385 18%
General and administrative 4,162,076 2,600,734 1,561,342 60%
Research and development 254,656 255,880 (1,224) (0)%
Change in contingent consideration (64,203) 31,749 (95,952) (302)%
Depreciation 207,617 151,072 56,545 37%
Amortization 549,123 439,699 109,424 25%
Total operating expenses $15,318,208 $8,268,203 $7,050,005 85%

Direct Operating Costs. Direct operating costs of $9.8 million for the three months ended March 31, 2019 increased by $5.4 million or 120% from direct operating costs of $4.5 million for the three months ended March 31, 2018. During the three months ended March 31, 2019, salary costs increased by $2.8 million and outsourcing and processing costs increased by $814,000, respectively. Facility costs increased by $396,000 for the three months ended March 31, 2019. Medical supplies for the managed practices were $1.2 million for the three months ended March 31, 2019. The increase in the costs for the three months ended March 31, 2019 were primarily related to the Orion acquisition.

Selling and Marketing Expense. Selling and marketing expense of $361,000 for the three months ended March 31, 2019 increased by $56,000 or 18% from selling and marketing expense of $305,000 for the three months ended March 31, 2018, respectively. The increase was primarily due to increased marketing expenditures.

General and Administrative Expense. General and administrative expense of $4.2 million for the three months ended March 31, 2019 increased by $1.6 million or 60% compared to the same period in 2018. The increase in general and administrative expense for the three months ended March 31, 2019 was primarily related to additional salaries, facility costs and professional fees as a result of the Orion acquisition.

Research and Development Expense. Research and development expense of $255,000 for the three months ended March 31, 2019 decreased by $1,000 from research and development expense of $256,000 or the three months ended March 31, 2018, respectively.

Contingent Consideration. The change in contingent consideration of $64,000 was due to a favorable settlement during the three months ended March 31, 2019. The change of $32,000 during the three months ended March 31, 2018 relates to the change in the fair value of the contingent consideration from acquisitions.

Depreciation. Depreciation of $208,000 for the three months ended March 31, 2019 increased by $57,000 or 37% from depreciation of $151,000 for the three months ended March 31, 2018 due to additional purchases and property and equipment acquired as part of the Orion acquisition.

Amortization Expense. Amortization expense of $549,000 for the three months ended March 31, 2019 increased by $109,000 from amortization expense of $440,000 for the three months ended March 31, 2018. The increase for the three months ended March 31, 2019 was primarily related to the intangible assets acquired from the Orion acquisition.

Three Months Ended March 31, 2019 2018 Change Amount Percent
Interest income $78,200 $5,285 $72,915 1,380%
Interest expense (95,396) (74,081) (21,315) (29)%
Other (expense) income - net (81,030) 151,374 (232,404) (154)%
Income tax (benefit) provision (40,532) 46,664 (87,196) (187)%

Interest Income. Interest income of $78,000 for the three months ended March 31, 2019 increased by $73,000 or 1380% from interest income of $5,000 for the three months ended March 31, 2018, respectively. The increase in interest income represents interest earned on temporary cash investments.

Interest Expense. Interest expense of $95,000 for the three months ended March 31, 2019, increased by $21,000 or 29% from interest expense of $74,000 for the three months ended March 31, 2018. This increase was primarily due to the additional vehicle financing during the three months ended March 31, 2019. Interest expense includes the amortization of deferred financing costs, which was $48,000 and $49,000 during the three months ended March 31, 2019 and 2018, respectively.

Other (Expense) Income - net. Other (expense) income - net was ($81,000) for the three months ended March 31, 2019, compared to other income - net of $151,000 for the three months ended March 31, 2018. Other income primarily represents foreign currency transaction gains (losses) resulting from transactions in foreign currencies other than the functional currency. These transaction gains and losses are recorded in the condensed consolidated statements of operations related to the recurring measurement and settlement of such transactions.

Income Tax (Benefit) Provision. There was a $41,000 benefit for income taxes for the three months ended March 31, 2019, compared to the provision for income taxes of $47,000 for the three months ended March 31, 2018. Included in the tax benefit for the three months ended March 31, 2019 is a $56,000 deferred Federal income tax benefit. As a result of the Company incurring a tax loss for 2018, which has an indefinite life under the recent tax reform legislation, the Federal deferred tax liability was offset against the 2018 Federal net operating loss, resulting in a Federal net deferred income tax benefit.

The current income tax provision for the three months ended March 31, 2019 was approximately $15,000 and primarily relates to state minimum taxes and foreign income taxes. Although the Company is forecasting a return to profitability, it incurred losses historically and there is uncertainty regarding future US taxable income, which make realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance was recorded against all deferred tax assets at March 31, 2019 and 2018.

Liquidity and Capital Resources

Borrowings under the SVB facility are based on 200% of repeatable revenue, reduced by an annualized attrition rate as defined in the agreement. The entire facility is currently available to the Company. As of March 31, 2019, nothing was drawn on the SVB credit agreement.

During the three months ended March 31, 2019, there was positive cash flow from operations of approximately $938,000 and as of March 31, 2019 the Company had approximately $12.5 million in cash, positive working capital of $14.5 million and no bank debt.

During 2018, the Company paid the purchase price of $12.6 million for the Orion acquisition. The Company occasionally utilizes its revolving line of credit with SVB, but, as of March 31, 2019, there was no balance outstanding. SVB doubled the maximum availability on the line from $5 million to $10 million in September 2018. During October 2018, the Company sold 600,000 additional shares of its Series A Preferred Stock raising net proceeds of approximately $13.4 million. During April 2018, the Company sold 420,000 shares of Series A Preferred Stock and raised net proceeds of approximately $9.4 million.

The following table summarizes our cash flows for the periods presented:

Three Months Ended March 31, 2019 2018
Net cash provided by operating activities $937,509 $673,381
Net cash used in investing activities (510,938) (174,242)
Net cash used in financing activities (2,586,271) (1,114,037)
Effect of exchange rate changes on cash 213,864 (206,264)
Net decrease in cash $(1,945,836) $(821,162)

The loss before income taxes was $336,000 for the three months ended March 31, 2019, which included $757,000 of non-cash depreciation and amortization. The income before tax for the three months ended March 31, 2018 was $122,000, which included $591,000 of non-cash depreciation and amortization.

Operating Activities

Cash provided by operating activities was $938,000 during the three months ended March 31, 2019, compared to $673,000 during the three months ended March 31, 2018. The increase in the net loss of $371,000 included the following changes in non-cash items: an increase in depreciation and amortization of $166,000, an increase in stock based compensation expense of $630,000, a change in the benefit for deferred income taxes of $94,000 and an increase in interest accretion of $71,000.

The change in operating assets and liabilities increased by $766,000. Accounts receivable increased by $481,000 for the three months ended March 31, 2019, compared with a decrease of $24,000 for the three months ended March 31, 2018. Accounts payable, accrued compensation and accrued expenses decreased by $765,000 for the three months ended March 31, 2019 compared to a decrease of $212,000 for the three months ended March 31, 2018. For the three months ended March 31, 2019, the change in the lease liabilities is included in this amount.

Investing Activities

Capital expenditures were $511,000 and $174,000 for the three months ended March 31, 2019 and 2018, respectively. The capital expenditures for the three months ended March 31, 2019 primarily represented computer equipment purchased for the Pakistan office.

Financing Activities

Cash used in financing activities during the three months ended March 31, 2019 and 2018 was $2.6 million and $1.1 million, respectively. Cash used in financing activities during the three months ended March 31, 2019 included $85,000 of repayments for debt obligations, $1.5 million of preferred stock dividends and $872,000 of tax withholding obligations paid in connection with stock awards issued to employees. Cash used in financing activities for three months ended March 31, 2018 included $93,000 of repayment for debt obligations, $755,000 of preferred stock dividends and $214,000 of withholding obligations in connection stock awards issued to employees. There were no borrowings during the three months ended March 31, 2019 and 2018.

Contractual Obligations and Commitments

We have contractual obligations under our line of credit and related to contingent consideration in connection with the acquisitions made in 2015 and 2016. We also maintain operating leases for property and certain office equipment. We were in compliance with all SVB covenants as of March 31, 2019. For additional information, see Contractual Obligations and Commitments under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 20, 2019.

Off-Balance Sheet Arrangements

As of March 31, 2019 and 2018, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special-purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

Market risk

As filed, 175 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are a smaller reporting company as defined by 17 C.F.R. 229.10(f)(1) and are not required to provide information under this item, pursuant to Item 305(e) of Regulation S-K.

Controls and procedures

As filed, 2,550 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, based on the 2013 framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2019 as required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures, as of March 31, 2019, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

Beginning January 1, 2019, we implemented ASC 842, “Leases.” For its adoption, we implemented changes to our lease identification processes and control activities within them such as development of new entity-wide policies, in-house training, ongoing contract reviews and system changes to accommodate presentation and disclosure requirements.

There were no other changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 147 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Pursuant to the instructions of Item 1A of Form 10-Q, a smaller reporting company is not required to provide the information required by this Item.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-01-01 to 2019-03-31$15.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2019-01-01 to 2019-03-31$254.7kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2019-01-01 to 2019-03-31−$238.0kus-gaap:OperatingIncomeLoss
Income tax3 months2019-01-01 to 2019-03-31−$40.5kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-01-01 to 2019-03-31−$295.7kus-gaap:NetIncomeLoss
Diluted EPS3 months2019-01-01 to 2019-03-31−$0.15us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2019-01-01 to 2019-03-31$937.5kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2019-01-01 to 2019-03-31$510.9kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2019-03-31$12.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-03-31$24.0mus-gaap:AssetsCurrent
Total assetsAt period end2019-03-31$49.3mus-gaap:Assets
Current liabilitiesAt period end2019-03-31$9.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-03-31$12.3mus-gaap:Liabilities
Shareholders' equityAt period end2019-03-31$37.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-19-006582. Last ingested by Listed: Nov 5, 2026, 18:58 ET. Listed shows no prices and gives no investment advice.